ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years
Xia Li
Matched on OpenAlex author ID A5121529666. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2025: 1 paper · 2026: 2 papers
Papers 3
- Inhibiting calreticulin palmitoylation enhances the efficacy of elesclomol-CuCl2 on oxaliplatin-triggered immunogenic cell death in pancreatic cancer. First author DOI 10.1016/j.phrs.2026.108459↗
- Indirect pharmacology of Amorphophallus rivieri Durieu in pancreatic ductal adenocarcinoma: immune-dependent macrophage remodeling and amino acid-related metab… Co-author DOI 10.21203/rs.3.rs-9321051/v1↗
- Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expression. Last author DOI 10.1007/s12032-025-03222-1↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhimiao Zou · 2 shared papers, 2025–2026 · strength 0.49
- Paper Inhibiting calreticulin palmitoylation enhances the efficacy of elesclomol-CuCl2 on oxaliplatin-triggered immunogenic c… DOI 10.1016/j.phrs.2026.108459↗
- Paper Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expres… DOI 10.1007/s12032-025-03222-1↗
- Yuhua Zhang · 2 shared papers, 2025–2026 · strength 0.49
- Paper Inhibiting calreticulin palmitoylation enhances the efficacy of elesclomol-CuCl2 on oxaliplatin-triggered immunogenic c… DOI 10.1016/j.phrs.2026.108459↗
- Paper Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expres… DOI 10.1007/s12032-025-03222-1↗
- Xiang Qian · 1 shared paper, 2026 · strength 0.30
- Qiao Liu · 1 shared paper, 2026 · strength 0.30
- Yuehua Chen · 1 shared paper, 2026 · strength 0.30
- Wenkai Ye · 1 shared paper, 2025 · strength 0.24
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.